Karyopharm Therapeutics (KPTI) to Release Quarterly Earnings on Thursday

Karyopharm Therapeutics (NASDAQ:KPTI) is expected to release its earnings data before the market opens on Thursday, March 6th. Analysts expect Karyopharm Therapeutics to post earnings of ($0.26) per share and revenue of $37.83 million for the quarter. Karyopharm Therapeutics has set its FY 2025 guidance at EPS.Persons interested in registering for the company’s earnings conference call can do so using this link.

Karyopharm Therapeutics (NASDAQ:KPTI) last announced its earnings results on Wednesday, February 19th. The company reported ($3.60) earnings per share for the quarter, topping the consensus estimate of ($3.90) by $0.30. The company had revenue of $30.54 million for the quarter, compared to analysts’ expectations of $30.29 million. On average, analysts expect Karyopharm Therapeutics to post $-1 EPS for the current fiscal year and $0 EPS for the next fiscal year.

Karyopharm Therapeutics Price Performance

Shares of KPTI stock opened at $6.37 on Wednesday. The firm has a market cap of $53.64 million, a PE ratio of -6.25 and a beta of 0.06. The company has a 50-day moving average of $9.77 and a two-hundred day moving average of $11.20. Karyopharm Therapeutics has a 1-year low of $5.95 and a 1-year high of $25.50.

Wall Street Analyst Weigh In

KPTI has been the subject of several recent research reports. StockNews.com lowered shares of Karyopharm Therapeutics from a “buy” rating to a “hold” rating in a research note on Friday, November 22nd. HC Wainwright raised their price objective on shares of Karyopharm Therapeutics from $7.00 to $56.00 and gave the company a “buy” rating in a research note on Wednesday, February 26th. Robert W. Baird lowered their price objective on shares of Karyopharm Therapeutics from $75.00 to $54.00 and set an “outperform” rating for the company in a research note on Monday. Piper Sandler raised their price objective on shares of Karyopharm Therapeutics from $60.00 to $75.00 and gave the company an “overweight” rating in a research note on Wednesday, November 6th. Finally, Royal Bank of Canada reissued an “outperform” rating and issued a $45.00 price objective on shares of Karyopharm Therapeutics in a research note on Thursday, February 20th. One investment analyst has rated the stock with a hold rating and four have issued a buy rating to the stock. According to MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $57.50.

Karyopharm Therapeutics Company Profile

Karyopharm Therapeutics Inc, a commercial-stage pharmaceutical company, discovers, develops, and commercializes drugs directed against nuclear export for the treatment of cancer and other diseases in the United States. The company discovers, develops, and commercializes novel and small molecule Selective Inhibitor of Nuclear Export (SINE) compounds that inhibit the nuclear export protein exportin 1 (XPO1).